Abstract:Abstract Background Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease whose pathophysiology involves the interplay between genetic and environmental factors, ultimately leading to dysfunction of the epidermis. While several treatments are effective in symptom management, many existing therapies offer only temporary relief and often come with side effects. For this reason, the formulation of an effective therapeutic plan is challenging and there is a need for more effective and targeted treatments that address the root causes of the condition. Here, we hypothesise that modelling the complexity of the molecular buildup of the atopic dermatitis can be a concrete means to drive drug discovery. Methods We preprocessed, harmonised and integrated publicly available transcriptomics datasets of lesional and non-lesional skin from AD patients. We inferred co-expression network models of both AD lesional and non-lesional skin and exploited their interactional properties by integrating them with a priori knowledge in order to extrapolate a robust AD disease module. Pharmacophore-based virtual screening was then utilised to build a tailored library of compounds potentially active for AD. Results In this study, we identified a core disease module for AD, pinpointing known and unknown molecular determinants underlying the skin lesions. We identified skin- and immune-cell type signatures expressed by the disease module, and characterised the impaired cellular functions underlying the complex phenotype of atopic dermatitis. Therefore, by investigating the connectivity of genes belonging to the AD module, we prioritised novel putative biomarkers of the disease. Finally, we defined a tailored compound library by characterising the therapeutic potential of drugs targeting genes within the disease module to facilitate and tailor future drug discovery efforts towards novel pharmacological strategies for AD. Conclusions Overall, our study reveals a core disease module providing unprecedented information about genetic, transcriptional and pharmacological relationships that foster drug discovery in atopic dermatitis.

The search for blood biomarkers useful in treating atopic dermatitis patients

Identification of Candidate Genes in Atopic Dermatitis Based on Bioinformatic Methods

Potential Biomarkers of Atopic Dermatitis

Biomarkers in Atopic Dermatitis

Identification of diagnostic molecules and potential therapeutic agents for atopic dermatitis by single-cell RNA sequencing combined with a systematic computing framework that integrates network pharmacology

Case Series Analysis of Late-Onset Atopic Dermatitis: Unraveling Clinical Variants

Exploring novel drug targets for atopic dermatitis through plasma proteome with genome

Molecular Biology of Atopic Dermatitis

Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies

Multiple Transcriptome Data Analysis Reveals Biologically Relevant Atopic Dermatitis Signature Genes and Pathways

Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives

Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches

Exploring the Potential of IL-4 and IL-13 Plasma Levels as Biomarkers in Atopic Dermatitis

Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies

Systemic Inflammatory Proteomic Biomarkers in Atopic Dermatitis: Exploring Potential Indicators for Disease Severity

Integrative network analysis suggests prioritised drugs for atopic dermatitis

Association between CCL5, CCL11, and CCL17 polymorphisms and atopic dermatitis risk: A systematic review and meta-analysis

Skin Predictive Biomarkers for the Development of Atopic Dermatitis and Food Allergy in Infants

Atopic Dermatitis and IgE-Mediated Food Allergy: Common Biologic Targets for Therapy and Prevention

Emerging Biologic Therapies for the Treatment of Atopic Dermatitis

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options